Anti-Mouse TCR β chain – Purified in vivo PLATINUM™ Functional Grade

Clone H57-597 is widely used in in vivo mouse studies primarily to deplete TCR ?/?-positive T cells, assess T cell function, and as a tool to modulate immune responses. The main applications include:

• In vivo T cell depletion: Systemic administration of H57-597 leads to prompt and substantial reduction of both CD4+ and CD8+ ?/? T cells in mice. This depletion is specific to T cells expressing the ?/? TCR complex (does not affect ?/? T cells).

• Immune modulation and tolerance induction: Transient treatment with H57-597 can induce long-lasting immunomodulatory effects, such as increased frequency of regulatory T cells (Tregs, specifically CD4+Foxp3+ subsets), suppression of antigen-specific T cell expansion, and prolonged allograft survival in transplantation models. In models of heart and skin allografting, H57-597 prevented expansion of antigen-reactive T cells and led to donor-specific tolerance without global immunosuppression.

• Functional studies: In immobilized form (e.g., coated on plates), H57-597 can activate T cells by crosslinking their TCRs in vitro, which is sometimes adapted for in vivo activation models. However, in vivo, its main reported effect is depletion rather than activation.

• Marker for T cell identification: H57-597 is also used as a phenotypic marker in flow cytometry to specifically identify mouse ?/? TCR-expressing T cells. When conjugated, it enables tracking and quantitation of ?/? T cells in tissues during or after treatment.

Key points:

• Clone origin: Armenian hamster monoclonal IgG, specific for the ?-chain constant region of murine ?/? TCR.
• Specificity: Recognizes ?/? T cell receptor; does not cross-react with ?/? T cells.
• Functional notes: Removal of preservatives like sodium azide is necessary before in vivo use to avoid toxicity.

In summary, H57-597 is a standard, well-characterized antibody for in vivo depletion, functional modulation, and detection of mouse ?/? T cells, with strong utility in immunology and transplantation tolerance studies.

Commonly used antibodies or proteins combined with H57-597 (which detects the TCR ? chain on mouse ?? T cells) in the literature include those targeting core T cell markers, activation markers, and other lineage- or function-associated proteins.

Frequently co-used antibodies and proteins with H57-597:

• CD3: Part of the TCR complex, often analyzed together with TCR? to identify mature T cells.
• CD4 and CD8: Coreceptors distinguishing helper versus cytotoxic T cell subsets are commonly stained alongside TCR?.
• CD44, CD62L: Activation and memory markers used to define naïve, central memory, and effector T cell populations.
• CD25, CD69, CD5: Early and late activation markers often included in panels with TCR? for assessment of T cell activation states.
• TCR??: Antibodies specific for the ?? TCR are used to gate out or specifically analyze ?? T cells, since H57-597 does not recognize these cells.
• Other viability dyes and lineage markers: Such as NK1.1 (to exclude or quantify NKT cells), B220 (for B cells), and viability dyes to exclude dead cells.

Proteins and applications:

• MHC tetramers: Used in combination for identification of antigen-specific TCRs.
• Cytokine detection reagents: For functional analyses, these may be used in conjunction with surface and TCR staining.

Typical applications combining H57-597 with other antibodies:

• Flow cytometry: Multicolor panels will nearly always include CD4, CD8, CD3, and sometimes CD44 or cytokine markers together with TCR?.
• Immunoprecipitation and cell separation: H57-597 may be used along with anti-CD3 or other lineage markers.

Context from key sources:

• According to GeneTex and BioLegend, H57-597 is "used as a phenotypic marker for T cells expressing the alpha-beta TCR" and "these receptors participate in a complex with CD3, and with co-receptors CD4 or CD8".
• Literature and common applications further confirm that staining for CD3, CD4, CD8, activation markers, as well as exclusion of ?? TCR cells with specific antibodies, is standard practice in panels involving H57-597.

In summary, H57-597 is nearly always combined with antibodies for CD3, CD4, CD8, and TCR??, and often with other markers such as CD44, CD62L, and activation markers, depending on the experiment's aim.

Clone H57-597 is a well-established monoclonal antibody that specifically binds the beta chain of the mouse alpha-beta T cell receptor (TCR?). It is widely cited for its use in immunological research, particularly for its roles in T cell phenotyping, activation, depletion, and immune modulation studies.

Key findings from H57-597 citations in scientific literature include:

• Specificity and Reagent Use: H57-597 recognizes a common epitope on the beta chain of the mouse ?? TCR, does not cross-react with ?? TCR, and is widely used as a marker for ?? T cells in mouse tissue—including thymocytes, NKT cells, and most peripheral T cells—for flow cytometry and immune cell phenotyping.

• Functional Activation and Cross-Linking: When used in immobilized form, H57-597 can cross-link surface TCR and mimic antigen-induced TCR signaling, resulting in T cell activation, cytokine production, proliferation, or apoptosis. This property is exploited to study T cell activation pathways and apoptosis mechanisms in vitro.

• In Vivo T cell Depletion and Immune Modulation: H57-597 has been used to deplete TCR?-expressing T cells in vivo, which is valuable for investigating the functional roles of T cells in various mouse models, including autoimmunity and graft tolerance.

• Induction of Immune Tolerance and Treg Expansion:

  • Transient in vivo treatment with H57-597 can induce long-term immune modulation, notably increasing the frequency of regulatory T cells (Tregs) while significantly reducing conventional T cells.
  • This "reset" of T cell composition leads to suppressed antigen-specific T cell responses and can result in prolonged allograft survival by generating donor-specific tolerance—effects mediated in part by Treg mechanisms.
  • The regulatory effects are specific to the antigens present during H57-597 treatment, without compromising general T cell function against unrelated antigens.

• Experimental Therapeutic Applications:

  • Cited work indicates H57-597 reduces T cell-mediated pathology in models of autoimmune diseases and transplantation, demonstrating its utility in inducing antigen-specific tolerance.

• Other Practical Notes: Removal of sodium azide is recommended before use in functional assays, as it can interfere with cell viability and function.

In summary, clone H57-597 is essential for murine T cell detection, experimental activation or depletion, and has revealed important mechanisms of T cell tolerance and immune regulation, especially via Treg induction.

Dosing regimens of H57-597 (anti-TCR? monoclonal antibody) vary considerably depending on the mouse model and experimental objective:

• C57BL/6 (B6) wild-type mice: A single intraperitoneal dose of 1 mg/kg H57-597 is commonly used. This dose significantly reduces CD4? (by ~60%) and CD8? (by ~40%) T cell numbers and transiently increases Treg (CD4?FoxP3?) cell frequency in secondary lymphoid organs. Higher doses (?1 mg/kg) induced similar regulatory effects, while recovery of T cell homeostasis began within 40–100 days after treatment.

• Bcl-2 transgenic mice (apoptosis-resistant): The same 1 mg/kg dose of H57-597 failed to reduce T cell numbers or enrich for Tregs, demonstrating model-specific efficacy depending on T cell susceptibility to apoptosis.

• BALB/c mice: In studies of anti-TCR/CD3 modulation, dosing regimens included:

  • Five doses of 50 ?g every 24 hours (total: 250 ?g)
  • Four doses of 25 ?g every 72 hours (total: 100 ?g)
  • Lower doses down to four doses of 1 ?g every 72 hours (total: 4 ?g)

  All dosing was intraperitoneal.

• NOD/ShiLtJ (non-obese diabetic) mice: For immune modulation/diabetes studies:

  • Five doses of 50 ?g every 24 hours (total: 250 ?g)
  • Four or three doses of 25 ?g every 72 hours (total: 100–75 ?g)
  • Lower regimens included three to four doses of 5 ?g, 2 ?g, or 1 ?g every 72 hours.
  • There was no clear dose-response in terms of diabetes remission, as lower and higher regimens showed similar efficacy in inducing remission (44–60%).

Key Points by Model:

• Strain, transgene status, disease status, and experimental aims strongly influence both the amount and schedule.
• Single high doses (e.g., 1 mg/kg) are standard for T cell depletion/regulatory studies in C57BL/6.
• Fractionated lower doses (1–50 ?g per injection, over days) are commonly used in diabetes/immunomodulation studies in NOD and BALB/c mice.

Route of administration is almost universally intraperitoneal in published regimens.

Summary table:

Dosing variations reflect the mouse strain, immune status, and experimental question.